BACKGROUND: Although cancer drug shortages are a persistent problem in oncology, little is known about the awareness and perspectives of the US population with respect to shortages. METHODS: In 2016, we administered a 13-item cross-sectional survey to 420 respondents who were randomly selected from an online, probability-based sample demographically representative of the adult US population with respect to sex, age, race/ethnicity, education, geography, and income. Analyses applied poststratification sampling weights to draw national inferences. RESULTS: Overall, 16% of respondents reported being aware of drug shortages. Those with a personal history of cancer were more likely to be aware (31% vs 14% [P 5 .03]). In the overall cohort, most reported wanting to be informed about a substitution due to shortage: 87% and 82% for major or minor differences in efficacy, and 87% and 83% for major or minor differences in side effects. Most also reported they would transfer care to avoid a substitution: 72% for major differences in efficacy, and 61% for major differences in side effects. Black respondents, the uninsured, the unemployed, those with lower income, and the less well-educated were all less likely to report that they would transfer care to avoid major differences in efficacy (all P < .05). CONCLUSION: These data suggest that the US population is largely unaware of cancer drug shortages. Moreover, if being treated for cancer, most people would want to know about drug substitutions, even if it were to result in only minor differences in efficacy or side effects. With more significant differences, many would transfer care.
INTRODUCTION
Drug shortages have received increasing attention, as inadequate supplies of key medications have the potential to impair patient care, raise health care costs, and hamper clinical trials. 1 Although oncology is not the only discipline affected by drug shortages, patients with cancer are particularly vulnerable. Many commonly used anti-neoplastic agents are generic, time-sensitive in their administration, and do not have readily available substitutes. 2 Indeed, most oncologists report having experienced drug shortages that affected patient care, 3, 4 and the past decade has shown shortages to become more frequent. 5, 6 In July 2017, the American Society of Health-System Pharmacists reported 134 drug shortages in the United States, with 12 antineoplastic agents, 7 including cisplatin, fludarabine, and etoposide. It is not just shortages of chemotherapies that have affected cancer care. For example, the generic immunotherapy BCG has experienced multiple shortages in recent years, 8 and dozens of other drugs used for oncology-related supportive care (such as antibiotics and steroid preparations) have also been affected.
Attempts to ameliorate shortages of anticancer agents have had only had partial success, [9] [10] [11] [12] and drug shortages have continued to cause treatment delays, changes in regimens, and missed or suboptimal doses. 3, 4 Therapeutic modifications can result in diminished effectiveness 4, 13 and more pronounced side effects. 14 Some of these may be modest, but prior examples have shown that differences can also be substantial. 13, 15 For example, when investigators from the Pediatric Hodgkin's Lymphoma Consortium examined the effect of substituting cyclophosphamide for mechlorethamine in treating children with Hodgkin lymphoma due to a shortage of the latter, 2-year event-free survival was reduced by 13% (P 5 .01).
Shortages can also necessitate choosing which patients to treat with the preferred regimen or sending patients to other practices for therapy administration. 3, 6 Moreover, because generic drugs are frequently included in oncology research protocols, shortages can slow trial accrual or require drug substitutions that complicate interpretation of clinical trial data. 16, 17 Some institutions have even reported reserving therapies in shortage for clinical trials, therefore limiting availability for nonenrolled patients.
Studies of cancer drug shortages have investigated the experiences and opinions of oncology providers or examined the economic impact of shortages, [3] [4] [5] but there are sparse data regarding how patients might approach any drug shortages. One study found that patients undergoing anesthesia for elective surgery would want to know about changes due to shortages, 18 but patients with cancer face unique medical and psychosocial challenges 19 and have reported different treatment priorities compared with those with other diseases. 20 Even less is known about the awareness and preferences of the general public when it comes to shortages affecting cancer care.
Using an online, probability-based sample representative of the adult US population, we aimed to assess awareness of cancer drug shortages and to determine whether knowledge of a shortage would affect individuals' decisions about cancer care. We also wanted to assess preferences for drug allocations in the setting of shortages. We hypothesized that the general population would be mostly unaware, that respondents would want to know about shortages only when they would result in major differences in efficacy or side effects, and that more generally, respondents would prioritize allocation to patients with cancer who are potentially curable.
METHODS

Survey
In October 2016, we developed a 13-item cross-sectional survey (see online Supporting Information). The survey assessed awareness of cancer drug shortages and provided several hypothetical vignettes in which, because of a shortage, a drug substitution was necessary. In each vignette, the substitute drug had either a major or minor difference in efficacy (15% decrease in how well it treats the cancer versus a 5% decrease) or major or minor difference in side effects (15% increased risk of severe rash versus 5% increased risk of mild rash). We then asked, using a 5-point Likert scale, whether respondents would want to be informed of the substitution and whether they would transfer their care to receive the original drug if it were available at another cancer center. Next, we asked respondents if cancer centers were to publish the drugs in shortage at their center, whether this would be a "big factor," "small factor," or not a factor in their decision about where to seek cancer care. Finally, we asked participants which patients with cancer they believed should have the highest priority to receive chemotherapies in shortage. Prior to administering the survey, we performed formal cognitive debriefing with iterative changes, achieving saturation after 14 participants. The DanaFarber Office for the Protection of Human Research Subjects deemed the study exempt from review.
Participants
Survey respondents were members of the GfK KnowledgePanel, an online panel developed to be representative of the civilian, noninstitutionalized, adult population in the United States and which has been used frequently in prior medical and health policy studies. [21] [22] [23] [24] To minimize participation bias, panelists are recruited randomly through probability-based random digit dialing and address-based sampling; they cannot "opt in." The KnowledgePanel samples respondents from the US Postal Service's Delivery Sequence File, which covers nearly all US households and includes those with unlisted numbers, without internet access, and without landline phones. In addition, if an individual without internet access is selected to participate in the KnowledgePanel, GfK provides the participant both an internet connection and a web-enabled device for free. Respondents for individual surveys are selected at random from the approximately 55,000 panel members. After a survey is completed, poststratification sampling weights are calculated such that, after their application, the respondents are representative of the US population in terms of sex, age, race/ethnicity, education, geography, and income. Sampling weights are frequently updated to match the most recently published demographic data from the Current Population Survey, 25 a monthly 60,000-household survey jointly administered by the US Census Bureau and the Bureau of Labor Statistics. KnowledgePanel members are incentivized with points that are awarded for survey completion and panel retention; points can be redeemed for modest rewards including cash, merchandise, or gift cards.
Analysis
All analyses applied poststratification sampling weights to draw national inferences. Descriptive statistics were used to summarize sociodemographic characteristics and the proportion of participants who were aware of shortages, would probably/definitely want to be informed about a drug substitution, probably/definitely transfer their care under each of the four hypothetical scenarios (minor/ major differences in side effects/efficacy), and would use publicly available shortage data as a big or small factor in selecting their cancer treatment center. We performed chi-squared analyses to test for associations between sociodemographic characteristics and awareness of shortages, desire to be informed of substitutions, willingness to Original Article transfer care, and shortage reports being a "big" factor in deciding where to seek care. All analyses were performed using Stata version 13.1.
RESULTS
Of 737 potential participants, 420 (57%) responded. The participant characteristics are provided in Table 1 , with application of sampling weights. Sixteen percent were aware of cancer drug shortages, most frequently from the news and the internet (68% and 27% of those who were aware of shortages, respectively). Individuals were more likely to be aware of drug shortages if they had had a personal history of cancer (31% vs 14% [P 5 .03]), greater level of education (eg, 10% among those who did not complete high school versus 23% among those with at least a college degree [P 5 .01]) or reported more sources of health information (e.g., 7% among those who reported zero sources and 23% among those who reported at least 3 sources of health information [P 5 .01; Table 2] ).
Most individuals reported probably/definitely wanting to be informed about a therapy substitution if it were to have major (87%) or minor (82%) differences in efficacy, or major (87%) or minor (83%) differences in side effects; however, only 72% of individuals reported they would probably/definitely transfer care to avoid major differences in efficacy, and fewer (46%) would do so for minor differences. In addition, 61% and 40% reported they would transfer cancer care if a substitute had major or minor differences in side effects (Fig. 1) . Fifty-eight percent of individuals reported that publicly available shortage data would be a "big factor" in deciding where to be treated. An additional 32% reported it would be a "small factor." Table 3 summarizes associations between demographic characteristics and the likelihood that individuals reported they would transfer cancer care in each of the 4 vignettes. Individuals with a personal history of cancer were less likely to report they would transfer their care to avoid minor differences in efficacy (23% vs 47% [P 5
.02]) but no other differences were seen between those with and without a personal history of cancer, including whether they would use publicly available shortage reports in deciding where to be treated.
Individuals who were black, uninsured, or unemployed were significantly less likely to report they would transfer care for major differences in side effects or efficacy, but not for minor differences in either. In addition, both lower-income and less well-educated respondents were less likely to report they would transfer care for major differences in efficacy. Finally, black, uninsured, and unemployed individuals were all less likely to report that shortage data would be a "big factor" in deciding where to seek treatment (38% for black vs 60% for white and 64% for Hispanic [P 5 .05]; 28% for uninsured vs 61% for insured [P .001]; 44% for unemployed vs 58% for employed and 69% for retired [P 5 .01]).
When asked to identify patients with cancer who should have the highest priority for treatment when faced with a cancer drug shortage, individuals most frequently chose "those who would die the soonest without the cancer drug" (35%) and least frequently selected "patients already undergoing treatment with the cancer drug" (16% [Fig. 2]) . No statistically significant differences were seen between the responses of those with and without a personal history of cancer or by race/ethnicity, employment, or insurance status.
DISCUSSION
Using a novel source of nationally representative data, our analysis suggests that the general population is largely unaware of cancer drug shortages. In addition, if being treated for cancer, most people would want to be informed about therapy substitutions even if there are only minor changes in efficacy or side effects. Many reported they would even transfer their cancer care to avoid a substitute with major difference in efficacy or side effects.
In contrast to our hypothesis, we found that over three-quarters of individuals wanted to know about even minor differences in side effects from a substitute cancer drug, likely a less important factor for oncologists when choosing substitutions. These data have clear clinical implications for providers: even if the impact is minimal, patients want to know when therapy substitutions are made. In addition, given that many respondents reported that access to shortage data at individual centers would affect their decisions regarding where to seek treatment, our data suggest that cancer centers could increase their patient-centeredness by publicly posting updated lists of drugs in shortage.
It is both difficult and important to engage patients in discussions regarding drug shortages. 26, 27 Such discussions carry the risk of increasing patient anxiety without a concurrent benefit, especially for those with aggressive cancers where treatment is time-sensitive. Still, our data suggest that people expect disclosure regarding shortages as part of the caregiving process. Perhaps more importantly, if patients and their caregivers are routinely made aware of shortages, either through individual discussions with their providers or through publicly reported shortage data, this may result in increased pressure to address the systemic factors that lead to shortages in the first place or to improve interinstitutional cooperation and develop regional shortage mitigation strategies. Unfortunately, our findings raise the concern that disclosure regarding cancer drug shortages could also exacerbate care disparities. Specifically, participants who were black, had a lower income, were less well-educated, were uninsured, or were unemployed were less likely to report they would transfer care for major differences in efficacy. In addition, black, uninsured, and unemployed individuals were less likely to use publicly reported shortage data in deciding where to seek treatment.
Similar concerns have been raised with other care delivery initiatives, such as public reporting of quality metrics and pay-for-performance programs both within and outside the field of oncology. 28, 29 One recent study implied that this worry might be well placed. 30 Because public reporting of shortages is not currently common practice, the effects of increased access to such data are unknown-yet, if reflective of patients' true behavior, it is possible that patients with a higher income and education would be more likely to encounter, understand, and have the resources to utilize publicly reported shortage measures. Consequently, if centers began to report on cancer drug shortages, the impact of this practice on health disparities would be a potential area of future investigation.
Whereas previous studies have suggested an ethical framework for choosing which patients should receive cancer drugs in shortage, 5, 31, 32 our respondents provided a novel source of insight regarding the preferences of health care consumers. We had hypothesized that our respondents would prioritize those patients with the highest chance of cure, but found that the most highly ranked-at about one-third-were patients who would "die the soonest" without the preferred cancer drug. Interestingly, close to one-third also reported they would prioritize the "youngest patients," with only one-fifth prioritizing patients who are "potentially curable." This lack of consensus highlights the complexity of this issue and underscores the need for ethical expertise when designing shortage-related policy.
Although our findings are likely reflective of the US population as a whole, we chose not to exclusively survey patients with cancer. First, to our knowledge, there is no national database of oncology patients that is both representative of the US population and amenable to surveys. Next, although the preferences of patients with cancer are of clear importance in addressing cancer drug shortages, patients themselves are not the only stakeholders who have an interest in effective and transparent management of such shortages. 32 Finally, the fact that we found no differences between those with and without a personal history of cancer in all but 1 of our hypothetical scenarios suggests that patients with cancer may react similarly when faced with similar situations Our analysis has other limitations. Given that we asked respondents to report their wishes using hypothetical scenarios, it is not possible to know whether these preferences would hold when faced with the reality of a cancer diagnosis and a therapy shortage. On the other hand, respondents reported graduated preferences consistent with the balance of potential benefits and challenges presented in each scenario. Specifically, a higher proportion of individuals would want to know about or would change providers to avoid drug substitutions with major as opposed to minor differences, and individuals were more likely to want to be aware of a shortage than to change providers in each shortage scenario. Such responses suggest that respondents did truly weigh both the benefits and the challenges inherent in each vignette. Finally, our cohort is potentially vulnerable to participation bias. We have attempted to address this issue using a recruitment methodology with random selection of participants who were blinded to the content of the survey at the time of recruitment, and with rigorous application of poststratification sampling weights. Regardless, given that our study included a written survey in English (Flesch-Kincaid school grade level of 8.9), 33 our findings may not be generalizable to those without the required language or literacy needed to participate.
In conclusion, our analysis suggests that most people in the United States are unaware of national cancer drug shortages, and, when faced with even minor consequences from cancer drug substitutions, the majority would want to know about the change. In addition, when the differences between preferred and substitute therapies are great, many reported they would transfer their care to receive the preferred regimen. We also found that several traditionally vulnerable populations were less likely to report they would transfer their care to avoid the negative impact of substitutions, suggesting that cancer drug shortages may represent a novel source of cancer-related health disparities.
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